Park Y-H, Hwang S, Park H-W, Park C-S, Lee H-J, Namgoong J-M, Yoon S-Y, Jung S-W, Song G-W, Park G-C, Jung D-H, Ahn C-S, Kim K-H, Moon D-B, Ha T-Y, Lee S-G
Department of Surgery, Division of Hepatobiliary Surgery and Liver Transplantation, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Transplant Proc. 2012 Apr;44(3):757-61. doi: 10.1016/j.transproceed.2012.01.055.
Adult liver transplantation (OLT) recipients occasionally show serious acute cardiopulmonary dysfunction, requiring intensive care. We assessed the role of extracorporeal membrane oxygenation (ECMO) support in adult recipients facing acute pulmonary failure and refractory to conventional mechanical ventilation and concurrent nitric oxide gas inhalation.
From January 2008 to March 2011, 18 adult OLT recipients at our institution required ECMO support: 12 due to pneumonia and 6 to adult respiratory distress syndrome. Their mean age was 55.7 ± 6.9 years and mean Model for End-stage Liver Disease score, 24.8 ± 8.5. Twelve patients had undergone living donor and six deceased donor OLT.
A venovenous access mode and concurrent continuous venovenous hemodiafiltration were used in all patients. There were no procedure-related complications. Eight patients (44.4%) were successfully weaned from ECMO upon the first attempt after a mean support of 11.9 ± 6.1 days, but the other 10 died due to overwhelming infection. Univariate analysis revealed no significant pre-ECMO risk factor for treatment failure but C-reactive protein concentration at the time of ECMO differed significantly among patients who did versus did not survive after ECMO.
ECMO as rescue therapy may be a final therapeutic option for OLT recipients with refractory pulmonary dysfunction who would otherwise die due to hypoxemia from severe pneumonia or adult respiratory distress syndrome.
成人肝移植(OLT)受者偶尔会出现严重的急性心肺功能障碍,需要重症监护。我们评估了体外膜肺氧合(ECMO)支持在面临急性肺衰竭且对传统机械通气和同时吸入一氧化氮气体治疗无效的成人受者中的作用。
2008年1月至2011年3月,我院18例成人OLT受者需要ECMO支持:12例因肺炎,6例因成人呼吸窘迫综合征。他们的平均年龄为55.7±6.9岁,终末期肝病模型平均评分为24.8±8.5。12例患者接受了活体供肝肝移植,6例接受了尸体供肝肝移植。
所有患者均采用静脉-静脉通路模式并同时进行连续性静脉-静脉血液透析滤过。无手术相关并发症。8例患者(44.4%)在平均支持11.9±6.1天后首次尝试成功脱离ECMO,但其他10例因严重感染死亡。单因素分析显示,ECMO治疗前无显著的治疗失败危险因素,但ECMO时的C反应蛋白浓度在ECMO后存活与未存活的患者之间存在显著差异。
ECMO作为抢救治疗可能是OLT受者难治性肺功能障碍的最终治疗选择,否则这些患者可能因严重肺炎或成人呼吸窘迫综合征导致的低氧血症而死亡。